Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical pharmacology

M M Reidenberg1

  • 1Cornell University Medical College, New York, NY, USA.

JAMA
|June 7, 1995
PubMed
Summary
This summary is machine-generated.

Understanding individual drug responses is crucial. Recent studies highlight why people react differently to the same medication dose, impacting clinical trial surrogate endpoints.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Should administration of coenzyme Q10 be recommended to patients with congestive heart failure?

Clinical pharmacology and therapeutics·2014
Same author

Cigarette smoking, coffee drinking, and ingestion of charcoal-broiled beef as potential modifiers of drug therapy and confounders of clinical trials.

The Journal of pharmacology and experimental therapeutics·2012
Same author

From adverse drug reactions to drug disposition to WHO and essential medicines to our discipline of clinical pharmacology.

Clinical pharmacology and therapeutics·2010
Same author

Can the selection and use of essential medicines decrease inappropriate drug use?

Clinical pharmacology and therapeutics·2009
Same author

A new look at the profession of clinical pharmacology.

Clinical pharmacology and therapeutics·2008
Same author

Essential medicines for the whole world.

Clinical pharmacology and therapeutics·2007

Area of Science:

  • Pharmacology
  • Clinical Trial Design
  • Personalized Medicine

Background:

  • The selection of appropriate drug effects to measure, known as surrogate endpoints, is a critical aspect of clinical trial design.
  • Recent clinical trials have underscored the importance and complexity of choosing effective surrogate endpoints.
  • Variability in individual patient responses to medications presents a significant challenge in drug development and treatment.

Purpose of the Study:

  • To explore the factors contributing to differential patient responses to identical drug dosages.
  • To provide insights into the challenges posed by inter-individual variability in drug efficacy and safety.
  • To inform the selection and validation of surrogate endpoints in clinical research.

Main Methods:

Related Experiment Videos

  • Review of recent clinical trial data and pharmacological studies.
  • Analysis of existing literature on pharmacogenomics and drug metabolism.
  • Investigation into patient-specific factors influencing drug action.

    • Main Results:

    • Identified key biological and genetic factors causing diverse reactions to the same drug dose.
    • Demonstrated that a single dose does not guarantee a uniform therapeutic effect across all patients.
    • Highlighted the limitations of traditional surrogate endpoints in capturing the full spectrum of drug effects.

    Conclusions:

    • Individual variability in drug response significantly impacts the interpretation of clinical trial results.
    • The choice of surrogate endpoints must account for inter-individual differences to accurately reflect drug efficacy.
    • Further research into personalized medicine approaches is essential for optimizing drug therapy.